CAJ | 학술논문

目的观察磷酸西格列汀联合二甲双胍对2型糖尿病患者的临床疗效.方法将85例初发的2型糖尿病患者随机分为西格列汀组(46例)及二甲双胍组(39例).西格列汀组每天予以西格列汀100 mg(1次服用),二甲双胍组予以二甲双胍1500 mg(分3次服用).2组治疗12周后,所有患者改为二甲胍1500 mg(分3次服用)联合西格列汀100 mg(1次服用)继续治疗12周.西格列汀组和二甲双胍组单一治疗12周后及西格列汀联合二甲双胍继续治疗12周后,观察患者空腹血糖(FBG)、餐后2h血糖(2 h BG)、糖化血红蛋白(HbA1c)、血脂(TG、TC、LDL-C、HDL-C)、胰岛素抵抗指数(HOMA-IR)、BMI.结果西格列汀组与二甲双胍组治疗后,FBG、2hBG、HOMA-IR、HbA1c明显下降[西格列汀组:(7.4±1.2) mmol/L比(9.6 ±2.4)mmol/L,(9.0±1.4) mmol/L比(13.2±3.4) mmol/L,(3.2±0.5)比(6.2±0.5),(7.1±1.1)％比(8.7±2.5)％；二甲双胍组:(7.3±1.1) mmo]/L比(9.5±2.5)mmol/L,(8.9±1.5) mmol/L比(13.6±3.2) mmol/L,(3.3±0.4)比(6.0±0.7),(6.7±1.2)％比(8.6±2.6)％；P＜0.05].联合西格列汀与二甲双胍治疗12周后,FBG、2hBG、HOMA-IR、HbA1c均进一步下降,分别为(6.7±1.1)mmol/L、(8.1±1.2)mmol/L、(2.3±0.3)、(6.3±1.3)％,与西格列汀组及二甲双胍组单一治疗12周后比较,差异有统计学意义(P ＜0.05或P＜0.01).结论西格列汀联合二甲双胍能使初发2型糖尿病患者血糖明显下降,具有很好的临床应用价值.
목적 관찰린산서격렬정연합이갑쌍고대2형당뇨병환자적림상료효.방법 장85례초발적2형당뇨병환자수궤분위서격렬정조(46례)급이갑쌍고조(39례).서격렬정조매천여이서격렬정100 mg(1차복용),이갑쌍고조여이이갑쌍고1500 mg(분3차복용).2조치료12주후,소유환자개위이갑고1500 mg(분3차복용)연합서격렬정100 mg(1차복용)계속치료12주.서격렬정조화이갑쌍고조단일치료12주후급서격렬정연합이갑쌍고계속치료12주후,관찰환자공복혈당(FBG)、찬후2h혈당(2 h BG)、당화혈홍단백(HbA1c)、혈지(TG、TC、LDL-C、HDL-C)、이도소저항지수(HOMA-IR)、BMI.결과 서격렬정조여이갑쌍고조치료후,FBG、2hBG、HOMA-IR、HbA1c명현하강[서격렬정조:(7.4±1.2) mmol/L비(9.6 ±2.4)mmol/L,(9.0±1.4) mmol/L비(13.2±3.4) mmol/L,(3.2±0.5)비(6.2±0.5),(7.1±1.1)％비(8.7±2.5)％；이갑쌍고조:(7.3±1.1) mmo]/L비(9.5±2.5)mmol/L,(8.9±1.5) mmol/L비(13.6±3.2) mmol/L,(3.3±0.4)비(6.0±0.7),(6.7±1.2)％비(8.6±2.6)％；P＜0.05].연합서격렬정여이갑쌍고치료12주후,FBG、2hBG、HOMA-IR、HbA1c균진일보하강,분별위(6.7±1.1)mmol/L、(8.1±1.2)mmol/L、(2.3±0.3)、(6.3±1.3)％,여서격렬정조급이갑쌍고조단일치료12주후비교,차이유통계학의의(P ＜0.05혹P＜0.01).결론 서격렬정연합이갑쌍고능사초발2형당뇨병환자혈당명현하강,구유흔호적림상응용개치.
Objective To observe clinical efficacy of sitagliptin phosphate combined with metformin for patients with newly diagnosed type 2 diabetes.Methods All 85 patients with newly diagnosed type 2 diabetes,were divided into sitagliptin group (46 cases)and metformin group(39 cases).The patients in sitagliptin group were treated with sitagliptin(100 mg),and the patients in metformin group were treated with mefformin (500 mg,3 times per day) for 12 weeks.After 12 weeks,all patients were treated with a combination drag therapy for 12 weeks.The fasting blood glucose (FBG),2-hour postprandial blood glucose (2 h BG),glycated hemoglobin (HbA1c),lipids (TG,TC,LDL-C,HDL-C),insulin resistance index (HOMA-IR),and body mass index (BMI) were detected.Results The FBG,2 h BG,HOMA-IR and HbA1c in sitagliptin group and metformin group after treatment for 12 weeks were lower than those before treatment [sitagliptin group:(7.4 ± 1.2) mmol/L vs (9.6 ± 2.4) mmol/L,(9.0 ± 1.4)mmoL/L vs(13.2 ±3.4) mmol/L,(3.2 ±0.5) vs(6.2 ±0.5),(7.1 ±1.1)％ vs(8.7 ±2.5)％ ;mefformin group:(7.3 ±1.1)mmol/L vs(9.5 ±2.5) mmol/L,(8.9 ± 1.5)mmol/L vs(13.6 ±3.2) mmol/L,(3.3 ±0.4)vs (6.0 ± 0.7),(6.7 ± 1.2) ％ vs (8.6 ± 2.6) ％ ; P ＜ 0.05].Mter treatment with sitagliptin combined with metformin for 12 weeks,the FBG,2 h BG,HOMA-IR and HbA1c were(6.7 ± 1.1) mmol/L,(8.1 ± 1.2) mmol/L,(2.3 ± 0.3),(6.3 ± 1.3) ％,respectively,and obvious lower than those post-treatment in sitagliptin group and mefformin group(P ＜ 0.05 or P ＜ 0.01).Conclusion For patients with new diagnosed type 2 diabetes,sitagliptin combined with metformin can decrease the blood glucose,and possess good value in clinic.